Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
December 15, 2016 14:36 ET
|
Genmab A/S
Company Announcement
Copenhagen, Denmark; December 15, 2016 – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, the persons below have...
Tildeling af restricted stock units til bestyrelsesmedlemmer, direktion og medarbejdere og tildeling af warrants til direktion og medarbejdere i Genmab
December 15, 2016 14:20 ET
|
Genmab A/S
Selskabsmeddelelse
København, Danmark, 15. december 2016 – Genmab A/S (Nasdaq Copenhagen: GEN) offentliggjorde i dag, at på et bestyrelsesmøde har bestyrelsen besluttet at tildele 32.748...
Grant of Restricted Stock Units to Board Members, Management and Employees and Grant of Warrants to Management and Employees in Genmab
December 15, 2016 14:20 ET
|
Genmab A/S
Company Announcement
Copenhagen, Denmark; December 15, 2016 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to grant 32,748 restricted stock units...
Europa-Kommissionen tildeler markedsføringstilladelse for Arzerra® (ofatumumab) i kombination med fludarabin og cyclofosfamid til behandling af recidiverende CLL
December 12, 2016 13:39 ET
|
Genmab A/S
Pressemeddelelse
Arzerra godkendt i EU til brug i kombination med fludarabin og cyclofosfamid til behandling af recidiverende CLL
Godkendelsen kommer efter anbefaling fra CHMP i november...
European Commission Grants Marketing Authorization for Arzerra® (ofatumumab) in combination with Fludarabine and Cyclophosphamide in Relapsed CLL
December 12, 2016 13:39 ET
|
Genmab A/S
Media Release
Arzerra approved in EU for use in combination with fludarabine and cyclophosphamide in relapsed CLL
Approval follows November CHMP recommendation
Approval based on data...
Genmab’s ASH 2016 Data Review Meeting
December 05, 2016 00:01 ET
|
Genmab A/S
Media Release
ASH 2016 Data Review Meeting to be held today in San Diego, California
Key Opinion Leaders to discuss daratumumab data presented at ASH 2016
Event to be...
Genmab afholder ASH 2016 Data Review møde
December 05, 2016 00:01 ET
|
Genmab A/S
Pressemeddelelse
Genmabs ASH 2016 Data Review møde afholdes i dag i San Diego, Californien
Førende opinionsdannere diskuterer daratumumab-data, som er blevet præsenteret på ASH...
Genmab afholder ASH 2016 Data Review møde
December 01, 2016 02:59 ET
|
Genmab A/S
Pressemeddelelse
Førende opinionsdannere vil diskutere daratumumab-data, som er blevet præsenteret på ASH-årsmødet 2016
Mødet vil være tilgængeligt som live webcast og blive gemt på...
Genmab to Hold ASH 2016 Data Review Meeting
December 01, 2016 02:59 ET
|
Genmab A/S
Media Release
Key Opinion Leaders to discuss daratumumab data presented at the 2016 ASH meeting
Meeting to be webcast live and archived on www.genmab.com
Copenhagen, Denmark;...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
November 28, 2016 05:46 ET
|
Genmab A/S
Company Announcement
Copenhagen, Denmark; November 28, 2016 – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, the person below has...